Bluebird Bio (BLUE) has shared an update.
Bluebird bio, Inc. has strengthened its board with the appointment of Michael Cloonan as a new Class I director starting June 20, 2024. Cloonan is set to receive an annual retainer and equity compensation in line with the company’s policy for non-employee directors, with his stock options and restricted stock units vesting over a three-year period. His appointment comes with a standard indemnification agreement, and there are no familial or undisclosed financial ties between him and the current company leadership or transactions that would necessitate regulatory disclosure.
For an in-depth examination of BLUE stock, go to TipRanks’ Stock Analysis page.
